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Abstract
Circulating tumor cells (CTCs) are exfoliated at various stages of cancer, and could provide invaluable information for the
diagnosis and prognosis of cancers. There is an urgent need for the development of cost-efficient and scalable technologies
for rare CTC enrichment from blood. Here we report a novel method for isolation of rare tumor cells from excess of blood
cells using gas-filled buoyant immuno-microbubbles (MBs). MBs were prepared by emulsification of perfluorocarbon gas in
phospholipids and decorated with anti-epithelial cell adhesion molecule (EpCAM) antibody. EpCAM-targeted MBs efficiently
(85%) and rapidly (within 15 minutes) bound to various epithelial tumor cells suspended in cell medium. EpCAM-targeted
MBs efficiently (88%) isolated frequent tumor cells that were spiked at 100,000 cells/ml into plasma-depleted blood. Anti-
EpCAM MBs efficiently (.77%) isolated rare mouse breast 4T1, human prostate PC-3 and pancreatic cancer BxPC-3 cells
spiked into 1, 3 and 7 ml (respectively) of plasma-depleted blood. Using EpCAM targeted MBs CTCs from metastatic cancer
patients were isolated, suggesting that this technique could be developed into a valuable clinical tool for isolation,
enumeration and analysis of rare cells.
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Introduction
As cancer progresses, malignant cells are shed into the blood
[1,2,3]. Circulating tumor cells (CTCs) could provide invaluable
information for the monitoring of tumor progression and
recurrence in cancer patients [1,2,3]. The successful identification
and isolation of CTCs is a major challenge akin to finding a needle
in a haystack: there are only a few CTCs per million of blood cells
circulating throughout the body.
At present, several assays for CTC isolation and analysis are on
the market or in clinical development. The most common strategy
for isolating CTCs from blood is based on the use of
immunomagnetic beads coated with anti-epithelial EpCAM
[4,5,6,7,8], the most commonly used marker for detecting
circulating tumor cells [7,9]. An immunomagnetic bead-based
CellSearch Assay (Veridex) has received U.S. Food and Drug
Administration approval for the detection of epithelial CTCs in
metastatic cancer patients. At present, this assay is the gold
standard for CTC isolation. The capturing efficiency of rare tumor
cells with magnetic beads ranges between 60–90% [10,11]. The
most significant limitations of the assay are its relatively long
processing time, non-specific carryover and contamination with
leukocytes [8,12,13,14]. Recently, the field of CTC isolation
witnessed a surge of technologies, including microfluidics and
filtration. These state-of-the-art technologies allow to isolate, count
and even to manipulate single CTCs [15,16,17,18]. At the same
time, there is a continuing interest in development and testing of
cost-efficient, scalable and simple technologies for CTC isolation.
Perfluorocarbon gas-filled microbubbles (MBs) are clinically
approved for injection as ultrasound contrast agents [19,20]. A
typical microbubble consists of a gas interior coated by a soft shell,
which could consist of either a lipid monolayer or protein (albumin).
Perfluorocarbon gas maintains the stability of MBs in the aqueous
phase and confers buoyancy [19]. Recently, we demonstrated that
anti-fluorescein antibody-coated buoyant MBs efficiently bound
and separated fluorescein-labeled erythrocytes in mouse blood [21].
Here we set out to test whether EpCAM-targeted MBs are capable
of sensitive and specific isolation of rare tumor cells from mouse and
human blood. Our data suggest that MBs efficiently and specifically
isolate tumor cells from plasma-depleted blood. We demonstrate
that buoyancy-based separation of tumor cells from complex cell
mixtures is feasible and could become a promising strategy to
immune marker-based fractionation and isolation of rare cells.
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Materials and Methods
1. Ethics statement
Collection of healthy blood from anonymous volunteers was
approved by the UC San Diego Institutional Review Board
(protocol 081077XT). Collection and usage of human specimens
from consenting patients was approved by the UC San Diego
Institutional Review Board (protocol 100936). All the participants
had to sign approved IRB approved consent form prior to blood
collection. All animal studies were conducted under UCSD
IACUC protocol (protocol S07388).
2. Reagents
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) was pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA),
2-distearoyl-sn-glycero-3-phospho-ethanolamine-N-[maleimide
(polyethylene glycol)-3400] (DSPE-PEG3400-Malemide) and
maleimide-polyethylene glycol 3400-succinimidyl valerate
(Mal-PEG-SVA) were purchased from Laysan Bio, Inc. (Arab,
AL, USA), polyoxyethylene (40) stearate was purchased from
Sigma. All lipids were stored as chloroform solution under
argon at 220uC. Traut’s reagent (22Iminothiolane) was
purchased from Thermo Fisher Scientific (Rockford, IL,
USA). The reagent was dissolved in double-distilled water at
5 mg/ml and stored in aliquots at 220uC. Ellman’s reagent
(5,5’-dithiobis-(2-nitrobenzoic acid), or DTNB) was purchased
from Thermo Fisher Scientific and stored as a dry powder at
24uC prior to use. Nuclear stain Hoechst 33342 trihydrochlor-
ide trihydrate (Invitrogen, Carlsbad, CA, USA) was stored
frozen as a 1 mg/ml solution in PBS. AffiniPure Rabbit Anti-
Mouse IgG, Fc Fragment Specific and ChromPure Rabbit IgG,
whole molecule was purchased from Jackson ImmunoResearch
(West Grove, PA, USA). Mouse anti-human CD326 (EpCAM)
antibodies was purchased from Bio Legend (San Diego, CA,
USA), as was purified rat anti-mouse CD326 antibody. Alexa
Fluor 488 mouse anti-pan Cytokeratin antibody (clone AE1/
AE3) was purchased from eBioscience (San Diego, CA, USA).
All antibodies were stored at 4uC prior to use. Zeba Spin
Desalting Columns were purchased from Thermo Fisher
Scientific.
3. MB and immunomagnetic bead preparation
MBs were prepared from a mixture of DSPC/PEG40 stearate/
DSPE-PEG3400-maleimide as described [21]. Briefly, lipids in
chloroform were mixed at 10:1:1 molar ratio in a 2 ml borosilicate
glass vial (100–300 nmoles total lipid) and dried under an argon
stream to form a thin lipid film. The film was rehydrated in 1 ml
phosphate-buffered saline (PBS, pH 7.4) at room temperature for
5 minutes. The lipid was further dispersed under gas perfluor-
ohexane (Alfa Aesar, Ward Hill, MA, USA) atmosphere by
sonication (30-second cycle, 3–5 cycles total) using a MISONIX
XL-2000 probe sonicator at power setting ‘1’ Excess phospholipid
membrane fragments and small MBs were removed by centrifu-
gation at 50 g for 1 minute, repeated three times. MBs were
resuspended in PBS at a concentration of <16109/ml. For
conjugation of the anti-human and anti-mouse EpCAM antibody,
maleimide-activated MBs were modified with anti-Fc fragment-
specific IgG. Reactive sulfhydryl groups were introduced in anti-Fc
IgG by reaction with Traut’s reagent. The thiolated antibody was
purified from excess Traut’s reagent using a Zeba Spin Desalting
Column. The number of thiol groups on the IgG molecules was
determined with Ellman’s reagent as described [22]. On average,
each antibody had 1.5 thiol groups. Immediately after purification,
the thiolated antibody was added to 26108 washed maleimide
activated MBs. The conjugation was allowed to proceed for
1 hour at room temperature on a rotating plate set at a low speed.
MBs were washed by centrifugation at low speed for three times.
The final MB concentration was .108 MB/ml. MBs were stored
in PBS at 4uC prior to use. For magnetic bead coating with anti-
EpCAM, 5 mm aminated magnetic beads in polystyrene matrix
(Micromod, Rostock, Germany) were reacted with excess
maleimide-PEG3400-SVA (Laysan Bio) for 1 hour, washed on a
magnet, and reacted with the thiol-activated Fc-specific antibody
and then anti-EpCAM antibody as described for MBs. Crosslinked
iron oxide nanoparticles were prepared as described [23].
4. Quantification of IgG coupling and comparison
between MBs and magnetic beads
The amount of IgG conjugated to the surface of MBs was
quantified by SDS-PAGE under reducing conditions. MBs were
dissolved in Laemmli sample buffer (Bio-Rad, Hercules, CA, USA)
and destroyed in a water-bath sonicator; the amount equivalent to
36107 MBs was subsequently loaded on the gel (in a duplicate)
and analyzed with SDS-PAGE and silver staining. For quantifi-
cation of the band intensities, the IgG standard curve was
prepared at the quantities of 4, 2, 0.667, 0.222, 0.074, and
0.025 mg IgG per lane. Detection of protein bands was performed
with a Silver Quest staining kit (Invitrogen) according to the
manufacturer’s instructions. The silver-stained gels were scanned
on a flatbed scanner and the intensity of the protein bands was
quantified using ImageJ software. The density of 50 kDa bands
(heavy IgG chain) was used for plotting the calibration curve and
for sample concentration calculations. To compare the conjuga-
tion of rat anti-mouse EpCAM to MBs and beads, Alexa 488-
labeled anti-rat IgG (Invitrogen) was used. After the labeling with
the fluorescent antibody, MBs and beads were placed on a slide
and multiple fluorescence images at 2006magnification were
taken using the same exposure time. The background was
subtracted and the integrated signal intensity of Alexa 488 on
MBs and magnetic beads was determined using ImageJ freeware
(Measure tool). The integrated intensity of each object was divided
by pixel area of the same particle to obtain an average intensity/
pixel value, which corresponds to the antibody density.
5. Cell culture
4T1 breast carcinoma cells were purchased from the American
Type Culture Collection (ATCC; Manassas, VA, USA). GFP-
positive 4T1 cells were kindly provided by Anticancer, Inc (San
Diego, CA). ASPC-1 and A549 cells were from ATCC. Pancreatic
cancer BxPC-3 cells were from the laboratory of Dr. Bouvet,
UCSD [24]. GFP-PC3 prostate cancer cells were from the
laboratory of Dr. Sugahara, Sanford-Burnham Medical Research
Institute [25]. All cells were grown in RPMI 1640 supplemented
with 10% heat-inactivated FBS and 100 mg/ml penicillin/
streptomycin. All the cell lines were cultured at 37uC in a
humidified incubator in the presence of 5% CO2.
6. Tumor cell binding
For MB and magnetic bead binding experiments, 16104 tumor
cells were added to an eppendorf tube in 1 ml of complete cell
medium, followed by the excess of anti-mouse EpCAM-MBs or
anti-mouse EpCAM magnetic beads (particle/cell ratio <100/1).
The cells and MBs/beads were mixed on a rotator at 10 rpm for
various times. The binding efficiency was determined after taking
an aliquot of the mixture and counting the percentage of MB/
bead rosettes under microscope.
Microbubbles for Cell Isolation
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7. Feasibility of cell isolation with MBs
The minimal MB size, as well as the number of MBs to lift up a
cell was calculated as follows. According to the Archimedes’ law,
the buoyancy force is proportional to the mass difference between
an object (cell, MB) and the water that would occupy the same
volume (excess mass, EM). For the MB to be able to lift the cell
upwards, the following condition should be fulfilled:
EMcellzEMMBv0
The excess mass of a cell (EMcell) is:
EMcell~
4
3
pR3cell(rcell{rwater)
Similarly, the MB excess mass EMMB of radius RMB will be:
EMMB~
4
3
pR3MB(rPFH{rwater)
Where rPFH is the density of perflorohexane gas (0.0106 g/ml),
and rcell is the density of the cancer cell (1.08 g/ml [26]).
The number of antibodies to hold a tumor cell and a MB
together was calculated from the tension force. When the MB-cell
complex is not rising or floating, the tension T is the sum of the
weight and the buoyancy force.
T~g( Vcellrcell{Vcellrwaterj j{ VMBrPFH{VMBrwaterj j)
This equation does not take into account the drag forces. If the
MB-cell complex is moving up, the drag on the cell will increase
the tension, and the drag on the bubble will decrease the tension.
For a 20 mm cell and a 9 mm MB at 300 g, the drag increases the
tension by ,13%.
8. Isolation of cells with MBs
For isolation experiments, anticoagulated (heparin) blood was
obtained from healthy donors and metastatic cancer patients.
Heparinized mouse blood was obtained from 6–15-week old BalB/
C mice at the Moores UCSD Cancer Center vivarium. Blood was
diluted 1:5 with PBS and centrifuged at 2000 g for 20 minutes at
room temperature, and plasma was carefully removed. The cells
were then resuspended in PBS to bring the suspension to the initial
blood volume. After this procedure, the concentration of plasma
was decreased to less than 10%. Tumor cells were spiked into
plasma-poor blood and MBs were added at 0.3-16107 MBs/ml
(Dynabeads Epithelial Enrich protocol calls for 16107 beads/ml
therefore magnetic beads were used at this concentration). The cells
and MBs/beads were mixed on a rotator at 10 rpm for various
times. Then, MBs were centrifuged at 100 g for 2 minutes, whereas
beads were separated with external magnet.
For experiments with high concentration of tumor cells, MB
layer after centrifugation was carefully harvested into an
eppendorf tube containing 500 l of medium, and washed 2 times
by centrifugation at 100 g. For magnetic beads, the slurry was
washed 3 times and resuspended in 500 ml of medium. In some
experiments, MBs were briefly (1 second) bath-sonicated to destroy
MBs. Brief sonication does not destroy or damage the tumor cells.
The total volume in the tube was measured, and the concentration
Figure 1. Synthesis of MBs for isolation. A, MBs were coated with anti-EpCAM antibodies in a two-step process as described in Methods; Based
on the quantification (Supplement), on average 367,000 anti-Fc IgG molecules were coupled to the surface of each MB via Michael addition; B, anti-
EpCAM was detected with Alexa 488-labeled secondary Ab. Size bar, 20 mm; C, Size distribution of IgG coated MBs as determined from microscopy
images.
doi:10.1371/journal.pone.0058017.g001
Microbubbles for Cell Isolation
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of the GFP+ cells was determined by counting with hemocytom-
eter.
To study the depletion of frequent tumor cells by flow
cytometry, an aliquot of blood layer after separating the MB
layer was collected, washed in PBS once and incubated in
erythrocyte lysis buffer (Pierce) according to the manufacturer’s
instructions. The leukocytes and tumor cells were then resus-
pended in 1% BSA/PBS buffer and stained with Alexa Fluor 488-
anti-mouse EpCAM antibody and PE-anti-mouse CD45 antibody
according to manufacturer’s instructions. The depletion of tumor
cells was analyzed on a FACSCalibur instrument (BD Biosciences,
San Jose, CA, USA) using FlowJo software.
For isolation and counting of rare spiked tumor cells, the top
MB layer was carefully collected and transferred onto a slide. A
Nikon E600 upright fluorescence microscope with SPOT RT
color camera (46magnification objective) was used to count the
number of GFP-positive tumor cells on the slide. For detection of
non-labeled tumor cells after isolation, MB layer was carefully
transferred onto a nitrocellulose membrane in order to immobilize
the isolated cells and to enable subsequent staining steps. MBs
were destroyed by addition of ice-cold methanol, the membrane
was blocked with mouse serum for 30 min and then stained for
pan-cytokeratin (epithelial marker), Hoechst (nuclear marker) and
optionally CD45 (leukocyte marker). For isolation of CTCs from
cancer patients, 7.5 ml blood was drawn from metastatic cancer
patients at the Moores Cancer Center, and the same procedure as
described above was performed.
Figure 2. Binding of MBs to cultured tumor cells. A, Anti-EpCAM MBs and control MBs were added at 100:1 ratio to a suspension of 100,000 4T1
mouse breast carcinoma cells in 1 ml cell medium and mixed for 15 min. Targeted MBs formed rosettes around the cells, while control MBs did not
show any binding. Size bar, 50 mm for both images; B, Magnetic beads (5 mm diameter) were decorated with the anti-EpCAM antibody according to
the strategy described in Fig. 1. Anti-EpCAM IgG was detected on MBs and beads using a secondary fluorescent antibody; the coating was
comparable for MBs and beads; C, MBs and beads were mixed with GFP-4T1 cells in 1 ml medium (100:1 ratio). The characteristic rosettes between
MBs and beads were observed after 15 min; D, Binding efficiency of MBs and magnetic beads was determined at different time points. Blue bars,
percentage of cells coated with beads; black bars, percentage of cells coated with MBs. After 1 min, anti-EpCAM MBs bound to 4T1 cells more
efficiently than anti-EpCAM magnetic beads (t-test, P = 0.0001, n = 3).
doi:10.1371/journal.pone.0058017.g002
Table 1. Tumor cell lines tested for anti-EpCAM MB binding.
Name Description MB binding efficiency
4T1 Mouse breast carcinoma, epithelial .85%
GFP-4T1 Mouse breast carcinoma, epithelial .85%
BxPC3 Human pancreatic adenocarcinoma, epithelial .90%
A549 Human lung adenocarcinoma, epithelial .90%
ASPC-1 Human pancreatic adenocarcinoma, epithelial .90%
GFP-PC-3 Human prostate cancer, epithelial .90%
JeKo-1 Lymphoma, non-epithelial ,2%
doi:10.1371/journal.pone.0058017.t001
Microbubbles for Cell Isolation
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Results
1. Preparation of EpCAM-targeted MBs
We prepared MBs modified with anti-EpCAM IgG as shown in
Figure 1A. The preparation of targeted MBs involved a two-step
conjugation. First, we conjugated the anti-Fc antibody to MBs via
maleimide chemistry, and then added the anti-EpCAM antibody.
After the conjugation and washing steps steps, MBs were larger
than 2 mm, with 60% of MBs sized between 3 and 8 mm (Fig. 1B),
and the median size of 5 mm. MBs prepared by the emulsification
method usually result in a broad size distribution [27]; microfluidic
manufacturing methods could be utilized in the future to control
MB size [28]. As determined by Western blotting (Fig. S1), on
average each MB had 3.76105 PEG-maleimide-coupled anti-Fc
IgG, which theoretically should correspond to 7.46105 anti-
EpCAM IgG.
2. Binding of MBs to tumor cells
In order to test the binding of MBs to tumor cells in suspension,
we first used mouse breast carcinoma 4T1 cells. These cells are of
epithelial origin and we verified that over 95% of the cells express
EpCAM (albeit the expression was heterogeneous, Fig. S2). MBs
were added to cells in 1 ml medium at 100:1 ratio. Following
1 hour of gentle mixing, the cells formed ‘rosettes’ with anti-
EpCAM MBs (Fig. 2A). Anti-EpCAM MBs attached to over 80%
of cells while non-targeted MBs did not show any appreciable
binding (Fig. 2A). In addition to mouse 4T1 cells, we tested the
binding to other epithelial cell lines, as summarized in Table 1.
Anti-human EpCAM MBs efficiently bound to prostate cancer
GFP-PC3 cells, lung adenocarcinoma A549 cells, and pancreatic
adenocarcinoma BxPC-3 and ASPC-1 cells but did not apprecia-
bly bind to non-epithelial lymphoma JeKo-1 cells. In order to
compare side-by-side the binding efficiency of MBs with
immunomagnetic beads, a current gold standard for the cell
isolation, we prepared 5 mm diameter anti-mouse EpCAM
magnetic beads using the same two-antibody approach (see
Methods) and the same PEG linker (PEG3400) as for MBs. The
conjugation resulted in comparable amounts of anti-EpCAM IgG
on MBs and beads (Fig. 2B, Fig. S3). MBs or beads were added
to GFP-tagged 4T1 cells at 100:1 ratio and mixed. Following
15 min incubation, 89.2% of tumor cells became coated with MBs
and 84.7% of cells coated with beads (Fig. 2C-D). Notably, MBs
formed rosettes with 82% of cells within 1 min incubation,
suggesting that MB–cell binding is very efficient and fast (Fig. 2D).
The fast binding kinetics is demonstrated in Movie S1. However,
there were always 10-15% of cells that were not coated by MBs or
beads. It is likely that these cells express lower numbers of EpCAM
molecules (Fig. S2) and therefore more difficult to bind.
3. Theoretical aspects of tumor cell isolation
We calculated the minimum size and number of MBs that need
to be attached to a tumor cell to enable the flotation. We
performed the calculation based on the balance of buoyancy and
weight forces acting on MBs and cells (Fig. 3A and Methods).
According to the Archimedes law, the flotation of cancer cells in
aqueous medium critically depends on the MB size and the
number of MBs per cell. For a 20 mm diameter cell, a single 9 mm
Figure 3. Theoretical feasibility of cell flotation after MB attachment. The number of MBs to pull up a cell and the force acting on the MB-
cell attachment was calculated based on the buoyancy law as described in Methods. A, In a non-viscous aqueous medium, cells and MBs experience
the buoyant force (F) and the gravitation force or weight (W). Tension (force acting to disrupt MB–cell attachment) is the sum of F and W. This scheme
does not take into account the forces acting in blood, such as drag (viscous resistance) and cell-cell interactions; B, Phase diagram showing the
balance of gravity and buoyant forces at different MB sizes and MB/cell ratios. Cell diameter of 20 mm was used for the calculations. In the red zone,
the weight of MB-cell complexes prevails and the complexes sediment; in the blue zone the buoyancy takes over and the complexes float.
Gravitational acceleration does not affect the direction of the MB-cell complexes but only increases the speed of movement and tension force; C,
Tension between a single 9 mm-diameter MBs and a 20 mm cancer cell as a function of g-force. Red line is the tension force; green line is the
calculated number of antibodies required for holding a MB and a cell together (assuming that the force to pull out a phospholipid from the
membrane is equal to 50 pN [29,30,31]).
doi:10.1371/journal.pone.0058017.g003
Microbubbles for Cell Isolation
PLOS ONE | www.plosone.org 5 March 2013 | Volume 8 | Issue 3 | e58017
diameter MB can pull the cell up (Fig. 3B). Since the median size
of our MBs was 5 mm, 5 MBs should be sufficient to lift up a
20 mm cell (Fig. 3B). Our binding data (Fig. 2) showed that on
average there were more than 5 MBs per cell, suggesting that the
isolation of cancer cells is practically feasible.
When targeted MBs become attached to the cell surface,
buoyancy and gravity forces create a tension on the MB–cell
attachment (Fig. 3A). The tension forces could be calculated and
the number of antibodies to withstand the tension force could be
estimated. For a single 9 mm MB attached and a 20 mm cell, the
calculated tension force at 1 g (no centrifugation) is 6.7 pN
(Fig. 3C). The force needed to disrupt one antibody-receptor
bond is between 50-80 pN [29,30]. The force needed to pull a
lipid molecule out of a lipid bilayer is similar [31]. That means a
single Ab is sufficient to hold the MB–cell complex together when
no centrifugation force is applied. At 100 g, about 13 antibodies
would be needed to hold the MB and the cell. The chance of
breaking the MB-cell connection increases linearly (if ignoring
drag forces) with centrifugation speed. At 1000 g, over 130
antibodies would be required to hold the MB–cell complex
together (Fig. 1C). The actual number of EpCAM molecules at
the MB–cell contact (0.2–0.5 mm2) is well below 100 [9]. Although
the tension forces decrease significantly in case multiple MBs are
attached per cell, we limited the centrifugation to 100 g in the
actual isolation experiments.
4. Isolation of frequent spiked tumor cells with MBs and
beads
To perform actual isolation of tumor cells from complex cell
suspensions, we spiked various amounts of tumor cells into plasma-
depleted (,10% plasma) blood. We used plasma-depleted blood
(hereafter ‘blood cells’) because MB stability is somewhat
decreased in whole blood (not shown), possibly due to gas mixing
and exchange [32]. Two sets of experiments were performed. In
order to reliably quantify the isolation efficiency with hemocy-
tometer or flow cytometry, the first set of experiments was done
with high concentration of spiked tumor cells (100,000-
1,000,000 cells/ml). High number of cells lowers the uncertainty
and experimental error associated with spiking rare cells. The
second set of experiments was performed with rare tumor cells (13-
24 cells/ml). Figure 4A demonstrates the workflow of our
experiments. Following isolation (the full procedure for MB
collection will be published elsewhere), MB layer was collected
either into an eppendorf tube for FACS and hemocytometer, or
directly on a slide for counting of rare cells (Fig. 4A).
For testing the isolation efficiency, 100,000 cells GFP-4T1 cells
were added to 1 ml blood cells followed by EpCAM MBs or
magnetic beads. Following isolation, the cells were counted with
hemocytometer (Figure 4B). EpCAM-targeted MBs and beads
isolated GFP-4T1 cells from blood cells with high efficiency
(8868.5% for MBs and 8466% for beads). Control IgG MBs and
Figure 4. Isolation of tumor cells with MBs and magnetic beads. Tumor cells were spiked into 1 ml of plasma-depleted mouse blood (see
Methods). Mouse EpCAM-targeted MBs and beads were added at 16107 MB/ml. Following gentle mixing for 15 minutes, MB layer was separated
from blood cells by centrifugation at 100 g for 2 minutes. Magnetic beads were separated with a neodymium magnet. A, Collection of the floating
MB layer on top depends on the downstream analysis (see Methods); B, After the isolation of MBs and beads, the cells were placed on a
hemocytometer grid (MBs were destroyed for 1 second with gentle sonication) and the GFP-positive cells were counted at low magnification (406).
MBs and beads showed similar numbers of GFP+ cells in the isolated (enriched) fraction and near absence of GFP+ cells in the blood cell (depleted)
fractions. For size reference, red outline shows the major 565 square of the hemocytometer; C, Quantification of isolation efficiency of GFP-4T1 cells.
D, Quantification of tumor cell depletion from blood cells with flow cytometry. One ml of blood cells was spiked with non-labeled 4T1 cells at
16106 cells/ml. Remaining blood cell fraction and the isolated MB fraction were analyzed for tumor cells after CD45 (leukocyte) and EpCAM staining
(as described in Methods). Red blood cells were lysed and gated out (left image, FSC/SSC plot). MBs efficiently depleted 4T1 cells, and enriched them
with 95.4% purity. A representative experiment out of two is shown.
doi:10.1371/journal.pone.0058017.g004
Microbubbles for Cell Isolation
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beads isolated 2.561.5 and 2.160.8 tumor cells, respectively
(Fig. 4C). To quantify the depletion and enrichment of tumor
cells with flow cytometry, 16106 GFP-4T1 cells were spiked into
1 ml mouse blood cells and isolated with anti-EpCAM MBs.
According to Fig. 4D, EpCAM+ cells constituted 46.8% of non-
RBC blood cells before, but only 4.31% after the addition and
separation of anti-EpCAM MBs (corresponding to about 90%
depletion efficiency). In the MB-enriched sample, tumor cells
comprised 95.4% of all cells (Fig. 4D), corresponding to a 47-fold
enrichment.
MBs and beads carried over some white blood cells (WBCs) in
these experiments. The number of WBCs was variable and was
dependent on experimental conditions. WBC carryover was
consistently higher for micron-sized magnetic beads than for
MBs or nano-sized crosslinked iron oxides (Fig. S4A). Interest-
ingly, in the MB layer some of the WBCs were passively entrapped
and not bound to the outer membrane of MBs (Fig. S4B),
suggesting that efficient washing steps could further decrease the
non-specific carryover.
5. Isolation of rare spiked cells and patients’ tumor cells
with MBs
CTCs are present in blood of metastatic cancer patients at
extremely low concentrations of a few cells per milliliter [11]. In
order to determine the isolation efficiency of rare cells, we spiked
plasma-depleted blood at a concentration of 13-24 tumor cells per
ml and recovered them with anti-EpCAM MBs. We used the
approach described in Fig. 4A to isolate and count the MB-attached
cells. In order to decrease the spiking error, we placed on a slide the
same number of cells as used for spiking and counted in parallel with
the isolated cells. When we added 13 GFP-4T1 cells into 1 ml blood
cells and isolated with anti-mouse EpCAM MBs, (Fig. 5A), MBs
recovered 86.4% of the cells (n= 3). When human prostate GFP-
PC3 cells were spiked into 3 ml blood cells (11 cells/ml) and isolated
with anti-human EpCAM MBs, 81.9% of the cells (n= 3) were
Figure 5. Isolation of rare cells with MBs. Rare tumor cells were added to plasma-depleted blood, isolated with MBs as described in Fig. 4A and
counted on a slide. In order to avoid spiking and counting errors, the same number of tumor cells that was added to blood cells prior to isolation
(typically in 5–10 ml volume) was placed on a slide and counted in parallel with the isolated sample; A, Mouse breast cancer GFP-4T1 cells were added to
1 ml blood and isolated with anti-mouse EpCAM MBs (n= 3). B, Prostate cancer GFP-PC-3 cells were added to 3 ml of plasma-depleted blood and
isolated with anti-human EpCAMMBs (n= 3); C, Pancreatic cancer BxPC3 cells were added to 7 ml plasma-depleted blood and isolated with anti-human
EpCAM MBs. Unlike the experiments with GFP-tagged cells, the isolated cells were stained with pan-cytokeratin antibody. A representative microscopic
field (206objective) shows the MB-isolated BxPC3 cells positive for CK (green). Hoechst-positive, CK-negative cells, which are presumably carryover
leukocytes, are also visible in the field. Arrow points to a tumor cell cluster; D, There was a 77% efficiency of isolation of BxPC3 cells from 7 ml (n= 3).
doi:10.1371/journal.pone.0058017.g005
Figure 6. Isolation of CTCs from blood of metastatic cancer
patients. A, Case 1 was invasive, moderately to poorly differentiated
esophageal adenocarcinoma with brain metastases; B, Case 2 was
metastatic clear cell carcinoma with brain metastases. In both cases,
CK+/CD45- cells, which are presumably CTCs were identified (also Fig.
S4). Some cells present mitotic figures and multinuclear morphology as
described before [34]. CK-/CD45+ cells (presumably leukocytes) are also
shown in a separate field (red).
doi:10.1371/journal.pone.0058017.g006
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recovered (Fig. 5B). In order to mimic the protocol for isolation of
CTCs from human patients (7.5 ml blood volume is the current
standard for CTC isolation using Veridex CellSearch kit [11]), we
spiked 171 non-labeled human pancreatic adenocarcinoma BxPC3
cells into 7 ml of plasma depleted blood (24 cells/ml) and isolated
them with 36107 MBs. The difference from the 1 ml and 3 ml
experiments was that the tumor cells post-isolation were stained for
pan-cytokeratin (epithelial marker) for identification. The tumor
cells were CK-positive/Hoechst-positive, whereas contaminating
leukocytes were CK- negative (Fig. 5C). Interestingly, MBs also
isolated BxPC-3 cell clusters (Fig. 5C, arrow). According to
Fig. 5D, MBs isolated 77.8% of the applied cells (n= 3). No CK-
positive cells were isolated from samples that were not spiked with
tumor cells (not shown).
As a preliminary study, the ability of targeted MBs to detect
CTCs from 7 ml blood of metastatic cancer patients was tested.
Case 1 was invasive, moderately to poorly differentiated esoph-
ageal adenocarcinoma with brain metastases. Case 2 was
metastatic clear cell carcinoma with brain metastases. Based on
the established CTC isolation methods [10,11], CK+/CD45+
nucleated cells were considered tumor cells, whereas CK-/CD45+
nucleated cells were categorized as leukocytes. As shown in
Figure 6A-B and in Figs. S5A-B, in both cases anti-EpCAM
MBs isolated CK-positive, CD45-negative cells (21 and 8 cells,
respectively).
Discussion
CTCs are quickly becoming a valuable diagnostic and
prognostic marker for individualized medicine [33]. Besides
counting CTCs numbers of as a prognostic marker, genetic
profiling and expression analysis of CTCs are a promising
approach for cancer prognosis and drug screening [33]. CTC
CTCs could be used for ‘blood biopsy’, i.e., exfoliated CTC are
used instead of tissue biopsy for diagnosis and drug testing. Since
CTCs are extremely rare and non-homogenous, sample prepara-
tion is a crucial parameter for downstream analytical techniques.
Here, we demonstrate that epithelial tumor cells could be
isolated from plasma-depleted blood using buoyant microbubbles
targeted to epithelial marker on the surface of tumor cells. To our
best knowledge, such a study has not been reported in literature.
Using EpCAM targeted MBs we achieved 88% isolation efficiency
of tumor cells spiked at high concentration (100,000 cells/ml) in
1 ml of plasma-depleted blood, and 77% isolation efficiency of
rare cells (23 cells/ml) spiked in 7 ml of plasma-depleted blood. In
addition to the spiking experiments, we were able to detect
cytokeratin-positive cells in blood of metastatic cancer patients,
including dividing and a multinuclear cells, similar to what was
reported for metastatic cancers [34]. It must be stressed that
currently accepted approach of identification of circulating tumor
cells relies on the presence of pan-cytokeratin epithelial marker
that does not identify CTCs per se, and more specific markers are
needed to positively identify tumor cells [35]. Based on the large
size of some of the isolated cells, high nucleus/cytoplasm ratio,
irregular shape of the nuclei, and appearance of mitotic figures we
suggest that MB-isolated cells are indeed tumor cells.
Sample preparation is one of the most critical aspects of
biospecimen analysis. Several important properties of MBs could
be very useful for CTC sample preparation, including speed,
potential scalability and simplicity. Thus, MB-cell binding takes
place faster than comparable immunomagnetic beads (within a
few minutes) as evidenced in Fig. 2D and Movie S1. For
example, speed of processing can improve the quality of tissue
expression analysis of CTCs. [36] Another important property of
perfluorocarbon MBs is that they are easy to eliminate in the final
sample (mild sonication or negative pressure), compared with
magnetic beads or microfluidic chip where the cells need to be
recovered with a proteolytic enzyme [17]. Non-specific contam-
ination with leukocytes is another serious problem for immuno-
magnetic CTC isolation [37,38]. Reducing a non-specific cell
contamination is critical for single genome analysis that usually
requires .1% purity of the target gene [38]. MBs resulted in some
carryover of leukocytes, which was less than with 5 mm magnetic
beads and similar with CLIO nanoparticles used in this study (Fig.
S4). Since there are many factors that affect isolation purity,
including surface properties (polystyrene vs. phospholipid vs.
hydrogel), cell concentration and washing, more extensive
comparison of purity of isolation needs to be performed before
drawing any conclusions regarding purity of this or that method.
Additional optimization of incubation/washing/collection steps as
well as improved MB formulation could further increase the level
of sample purity in order to enable sensitive and specific analysis of
the CTC genome. So far, the main limitation of the method is MB
instability in whole blood, necessitating washing steps prior to
application of MBs. Some of the instability of MBs in whole blood
is possibly due to gas mixing and exchange [32]. With correct
formulation and gas composition the stability of MBs could be
significantly improved [39].
We are confident that the technical challenges could be solved
and MBs could evolve into an attractive CTC isolation approach
for personalized medicine.
Supporting Information
Figure S1 Quantification of IgG on MBs. A, MBs were
destroyed in a water-bath sonicator, the amount equivalent to
36107 MBs was loaded on the gel (in a duplicate) and analyzed
with SDS-PAGE and silver staining. For quantification of the
band intensities, the IgG standard curve was prepared at the
quantities of 4, 2, 0.667, 0.222, 0.074 and 0.025 mg IgG per lane.
B, Standard curve was generated by measuring integrated band
intensity with ImageJ software. Based on the quantification, on
average 367,000 antibody molecules were coupled to the surface of
each MB via Michael addition.
(TIFF)
Figure S2 EpCAM expression on 4T1 cells. Analysis of
EpCAM levels was performed by FACS analysis. Per sample,
1.06106 cells were stained with Alexa-488 conjugated mouse anti-
human EpCAM antibody for 30 minutes at 4uC. Cells were then
washed three times with FACS buffer. All the samples were
analyzed on a FACSCalibur instrument (BD Biosciences, San Jose,
CA, USA). The acquisition was set to 50,000 events. The cell
population was gated on a FSC/SSC plot, and mean fluorescence
intensity and percentage of FL-2 positive cells was determined
using FlowJo software.
(TIFF)
Figure S3 Anti-EpCAM coating of MBs and beads. This is
a representative non-cropped image from Fig. 2B of fluorescent
antibody-stained MBs and beads for the comparison of anti-
EpCAM coating.
(TIFF)
Figure S4 Non-specific carryover of white blood cells
(WBCs) with MB fraction. IgG MBs (16107), IgG magnetic
beads (16107) and IgG CLIO were added to 7 ml of plasma-
depleted human blood and incubated for 15 minutes at RT. MBs
were separated as described in Fig. 4; magnetic beads were
separated with a magnet, CLIO were separated with Miltenyi
Microbubbles for Cell Isolation
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58017
MIDI column. Nucleated cells (white blood cells) were stained with
Hoechst nuclear dye and counted with a hemocytometer. A,
Amounts of WBCs after isolation. WBCs are present in all
fractions, but magnetic bead fraction consistently contained
significantly more WBCs that MBs and CLIO. Size bar,
100 mm; B, The image shows that some WBCs are not attached
to MBs.
(TIFF)
Figure S5 Images of CK+/CS45- cells the MB layer after
isolation from metastatic cancer samples. A and B correspond to
Fig. 6A-B.
(TIFF)
Movie S1 Isolation of tumor cells from PBS. Formalin-
fixed, DiI-labeled 4T1 cells (approximately 16106) were added to
3 ml PBS, followed by 36107 EpCAM-targeted or control MBs.
The cells were mixed and allowed to separate. The targeted MB
bound and separated cells within 7 min.
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